HC Wainwright & Co. Maintains Buy on Rani Therapeutics Hldgs, Raises Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has maintained a Buy rating on Rani Therapeutics Hldgs (NASDAQ:RANI) and increased the price target from $12 to $13.

May 07, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reaffirmed its Buy rating on Rani Therapeutics Hldgs and raised the price target from $12 to $13.
The upgrade in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100